Jeffrey J. Siracuse

Jeffrey J. Siracuse

Auto-generated profile, based on publicly available information

Jeffrey J. Siracuse

Boston Medical Center

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
AFAlik Farber
Alik Farber
MMMatthew T. Menard
Matthew T. Menard
MCMichael S. Conte
Michael S. Conte
JKJohn A. Kaufman
John A. Kaufman
RPRichard J. Powell
Richard J. Powell
KRKenneth Rosenfield
Kenneth Rosenfield
Patients with chronic limb-threatening ischemia (CLTI) require revascularization to improve limb perfusion and thereby limit the risk of amputation. It is uncertain whether an initial strategy of endovascular therapy or surgical revascularization for CLTI is superior for improving limb outcomes.

1 April 2016 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JSJeffrey J. Siracuse
Jeffrey J. Siracuse
MMMatthew T. Menard
Matthew T. Menard
MEMohammad H. Eslami
Mohammad H. Eslami
JKJeffrey A. Kalish
Jeffrey A. Kalish
WRWilliam P. Robinson
William P. Robinson
AFAlik Farber
Alik Farber

1 April 2020 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
SLScott R. Levin
Scott R. Levin
NANkiruka Arinze
Nkiruka Arinze
JSJeffrey J. Siracuse
Jeffrey J. Siracuse

1 April 2017 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JSJeffrey J. Siracuse
Jeffrey J. Siracuse
KOKathryn Van Orden
Kathryn Van Orden
JKJeffrey A. Kalish
Jeffrey A. Kalish
MEMohammad H. Eslami
Mohammad H. Eslami
MSMarc L. Schermerhorn
Marc L. Schermerhorn
AFAlik Farber
Alik Farber

4 January 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NANkiruka V. Arinze
Nkiruka V. Arinze
WYWenqing Yin
Wenqing Yin
SLSaran Lotfollahzadeh
Saran Lotfollahzadeh
MNMarc Arthur Napoleon
Marc Arthur Napoleon
SRSean Richards
Sean Richards
VCVipul Chitalia
Vipul Chitalia
Chronic kidney disease (CKD) imposes a strong and independent risk for peripheral artery disease (PAD). While solutes retained in CKD patients (uremic solutes) inflict vascular damage, their role in PAD remains elusive. Here, we show that the dietary tryptophan-derived uremic solutes including indoxyl sulfate (IS) and kynurenine (Kyn) at concentrations corresponding to those in CKD patients suppress β-catenin in several cell types, including microvascular endothelial cells (ECs), inhibiting Wnt activity and proangiogenic Wnt targets in ECs. Mechanistic probing revealed that these uremic solutes downregulated β-catenin in a manner dependent on serine 33 in its degron motif and through the aryl hydrocarbon receptor (AHR). Hindlimb ischemia in adenine-induced CKD and IS solute–specific mouse models showed diminished β-catenin and VEGF-A in the capillaries and reduced capillary density, which correlated inversely with blood levels of IS and Kyn and AHR activity in ECs. An AHR inhibitor treatment normalized postischemic angiogenic response in CKD mice to a non-CKD level. In a prospective cohort of PAD patients, plasma levels of tryptophan metabolites and plasma’s AHR-inducing activity in ECs significantly increased the risk of future adverse limb events. This work uncovers the tryptophan metabolite/AHR/β-catenin axis as a mediator of microvascular rarefaction in CKD patients and demonstrates its targetability for PAD in CKD models.

1 July 2017 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
EIElica Inagaki
Elica Inagaki
AFAlik Farber
Alik Farber
MEMohammad H. Eslami
Mohammad H. Eslami
JKJeffrey Kalish
Jeffrey Kalish
DRDenis V. Rybin
Denis V. Rybin
JSJeffrey J. Siracuse
Jeffrey J. Siracuse